Nektar Therapeutics (NKTR) Reaches $83.03 After 9.00% Up Move; First Bancorp (FBNC) Sentiment Is 2.71

May 18, 2018 - By Nellie Frank

First Bancorp (NASDAQ:FBNC) Logo

The stock of Nektar Therapeutics (NASDAQ:NKTR) is a huge mover today! The stock increased 4.80% or $3.7999 during the last trading session, reaching $83.0299. About 1.26 million shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since May 18, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.The move comes after 7 months positive chart setup for the $14.23B company. It was reported on May, 18 by Barchart.com. We have $90.50 PT which if reached, will make NASDAQ:NKTR worth $1.28B more.

First Bancorp (FBNC) investors sentiment increased to 2.71 in Q4 2017. It’s up 1.65, from 1.06 in 2017Q3. The ratio improved, as 92 funds opened new or increased stock positions, while 34 sold and decreased stock positions in First Bancorp. The funds in our database now have: 17.80 million shares, up from 16.40 million shares in 2017Q3. Also, the number of funds holding First Bancorp in top ten stock positions increased from 2 to 3 for an increase of 1. Sold All: 14 Reduced: 20 Increased: 61 New Position: 31.

Since December 13, 2017, it had 0 buys, and 21 insider sales for $88.95 million activity. $201,212 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Doberstein Stephen K on Friday, February 16. 40,000 shares were sold by KUEBLER CHRISTOPHER A, worth $3.90M. $10.93M worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by ROBIN HOWARD W. $288,382 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Labrucherie Gil M on Friday, February 16. 2,875 shares valued at $238,453 were sold by Hora Maninder on Friday, February 16. Shares for $2.30 million were sold by CHESS ROBERT on Friday, April 6. Lingnau Lutz also sold $3.05 million worth of Nektar Therapeutics (NASDAQ:NKTR) shares.

Investors sentiment decreased to 1.19 in 2017 Q4. Its down 0.21, from 1.4 in 2017Q3. It fall, as 18 investors sold Nektar Therapeutics shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Swiss Bancorp stated it has 0.02% in Nektar Therapeutics (NASDAQ:NKTR). Schroder Inv Mngmt Grp accumulated 0% or 14,016 shares. Genesee Valley has 4,366 shares for 0.11% of their portfolio. 2.02M are owned by Wellington Mngmt Grp Llp. Tocqueville Asset Lp invested 0.21% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). First Light Asset Management Lc holds 351,741 shares. Principal Fincl Group Inc holds 1.41M shares. 446 were reported by Glenmede Tru Com Na. Zeke Capital Advsr Ltd Llc reported 0.04% in Nektar Therapeutics (NASDAQ:NKTR). Paradigm Asset Mngmt Co Ltd Liability has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Fiera has invested 0.04% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Moreover, Alexandria Ltd Company has 0.87% invested in Nektar Therapeutics (NASDAQ:NKTR). Sectoral Asset Management stated it has 0.88% in Nektar Therapeutics (NASDAQ:NKTR). Columbus Circle Invsts has 242,114 shares for 0.27% of their portfolio. Deutsche Bancshares Ag holds 0.01% or 370,002 shares.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on August, 14. They expect $0.27 earnings per share, up 169.23% or $0.66 from last year’s $-0.39 per share. NKTR’s profit will be $46.28M for 76.88 P/E if the $0.27 EPS becomes a reality. After $-0.60 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -145.00% EPS growth.

More important recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Fool.com which released: “Here’s Why Nektar Therapeutics Fell as Much as 11.1% Today” on May 17, 2018, also Seekingalpha.com published article titled: “Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise”, Nasdaq.com published: “3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies …” on May 11, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) was released by: Seekingalpha.com and their article: “Nektar’s (NKTR) CEO Howard Robin on Q1 2018 Results – Earnings Call Transcript” with publication date: May 11, 2018.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $14.23 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Among 11 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 28 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by Roth Capital given on Thursday, July 20. The rating was maintained by Roth Capital on Monday, November 13 with “Buy”. Roth Capital maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Tuesday, May 30. Roth Capital has “Buy” rating and $3100 target. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Wednesday, October 18 by Jefferies. H.C. Wainwright reinitiated the stock with “Buy” rating in Monday, April 2 report. Canaccord Genuity maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Wednesday, January 10. Canaccord Genuity has “Buy” rating and $80.0 target. The stock has “Buy” rating by Aegis Capital on Monday, June 5. On Wednesday, August 26 the stock rating was downgraded by TheStreet to “Hold”. Mizuho maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Thursday, March 29. Mizuho has “Buy” rating and $8900 target. The firm has “Buy” rating by Canaccord Genuity given on Thursday, November 9.

Seidman Lawrence B holds 9.77% of its portfolio in First Bancorp for 362,407 shares. Jcsd Capital Llc owns 165,000 shares or 4.86% of their US portfolio. Moreover, Mendon Capital Advisors Corp has 3.09% invested in the company for 918,654 shares. The Massachusetts-based Castine Capital Management Llc has invested 2.2% in the stock. Stieven Capital Advisors L.P., a Missouri-based fund reported 337,879 shares.

Since January 1, 0001, it had 1 buy, and 1 sale for $15,824 activity.

First Bancorp operates as the bank holding firm for First Bank that provides banking services and products for individuals and small to medium-sized businesses primarily in North Carolina and northeastern South Carolina. The company has market cap of $1.21 billion. It accepts deposit products, such as checking, savings, and money market accounts, as well as time deposits, including certificates of deposits and individual retirement accounts. It has a 22.49 P/E ratio. The firm also offers loans for a range of consumer and commercial purposes comprising loans for business, agriculture, real estate, personal uses, home improvement, and automobiles.

The stock decreased 0.63% or $0.26 during the last trading session, reaching $40.93. About 52,921 shares traded. First Bancorp (FBNC) has risen 23.28% since May 18, 2017 and is uptrending. It has outperformed by 11.73% the S&P500.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>